PureTech Health PLC (PRTC)

Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell

124.20p

Buy

125.40p

arrow-up1.40p (+1.13%)

Prices updated at 09 May 2025, 16:35 BST
| Prices minimum 15 mins delay
|
Prices in GBX
PureTech Health PLC is a cross-disciplinary healthcare company developing products that could improve the lives of patients.
FTSE All-Share
arrow-up0.27%
LSE
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Biotechnology
Chairman
Dr. Raju S. Kucherlapati
CEO
Dr. Bharatt M. Chowrira
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
90
Head office
6 Tide Street
Boston
United States
02210
mobile
+1 617 482-2333
letter
ir@puretechhealth.com
computer
Company website

Key personnel

Owner name
chevron-l-regular
chevron-r-regular
Salary
Dr. John L. LaMattina, PhD
Senior Independent Director
-
Ms. Sharon Barber-Lui
Independent Director
-
Dr. Bharatt M. Chowrira
Director and Chief Executive Officer
-
Dr. Robert S. Langer, Sc.D.
Director
-
Dr. Raju S. Kucherlapati
Chairman of the Board
-

Top 5 shareholders

Owner name
chevron-l-regular
chevron-r-regular
No. of shares
Invesco Asset Management Ltd41,011,890
Invesco UK Equity High Income Fund (UK)28,188,790
UWS Invesco Perpetual Income12,823,100
Citigroup Inc12,004,514
Baillie Gifford & Co Limited.10,173,999

Director dealings

Date
chevron-l-regular
chevron-r-regular
Action
26 Feb 2025Transfer in
29 Oct 2024Transfer in
26 Jun 2024Transfer in
26 Jun 2024Transfer in
26 Jun 2024Transfer in
26 Jun 2024Transfer in
26 Jun 2024Transfer in
24 Jun 2024Sale
24 Jun 2024Sale
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.